Testing for mismatch repair deficiency remains underused among adults with colorectal cancer, despite the existence of well-established guidelines aimed at high-risk populations. READ MORE
Important factors to consider when developing a clinical pathway for colorectal cancer.
Chemoradiotherapy and post-operative chemotherapy may be equally effective when treating patients with gastric cancer.
Lymph node ratio may be a significant indicator of prognosis in patients with rectal cancer and could be used to better stratify patients in trials.
The physical location of a primary tumor may be an indicator of survivor in patients with metastatic colorectal cancer.
Recent research has uncovered an association between tumor origin and mortality among patients receiving systemic chemotherapy plus biologic therapy for metastatic colorectal cancer.
Sequencing cell-free DNA may be able to provide baseline information on actionable mutations and improve the quality of care in colorectal cancer.
A re-analysis of 2016 data from the USPSTF on colorectal cancer screening indicates that flexible sigmoidoscopy reduces the risk of death.
Systemic inflammation combined with sarcopenia could double the risk of death in patients with colorectal cancer, suggesting that these markers have clinical predictive value.
Research in Review
Patients aged 45 years or younger with colorectal cancer may have better treatment options available to them because of more mutations in their tumors than older patients.
Patients with rectal cancer who undergo first-line chemotherapy and radiation have lower risk of recurrence and higher rates of survival regardless of whether they choose to have surgery.
Patients with colorectal cancer can decrease their risk of disease-related mortality by 54% if they consume certain types of food.
Patients with a specific type of metastatic colorectal cancer who are chemotherapy-resistant benefit from treatment with a gene-targeting regimen.